Patents by Inventor Henrik Mueller

Henrik Mueller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220177075
    Abstract: A rear derailleur is provided for the coaxial attachment on a portion of a bicycle frame rear tail while using an adapter that includes an adapter bolt and an adapter nut and has a dual-arm base element, a pivoting mechanism, a movable element and a chain guide assembly. The reference is distinguished by at least one engagement element which facilitates an indirect frictional engagement between the adapter nut, on the one hand, and at least one of a) an inner first arm of the base element, b) an axial internal side of the mounting portion and c) the adapter bolt, on the other hand. Said engagement element, in a defined pre-assembled state, acts in the sense of a reinforcement of a consequential rotational force being able to be exerted on the base element by the adapter bolt and the adapter nut.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 9, 2022
    Applicant: SRAM DEUTSCHLAND GmbH
    Inventors: Henrik BRAEDT, Matthias MUELLER
  • Publication number: 20220096527
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits hepatitis B virus (HBV) infections. The compound (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; and is identified as a compound that prevents, ameliorates and/or inhibits HBV infections. An inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing HBV infections; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of HBV infections is also provided. The present invention includes a 10-pharmaceutical composition for use in treatment and/or prevention of HBV infections, and a method for monitoring therapeutic success during treatment of HBV infections.
    Type: Application
    Filed: December 3, 2021
    Publication date: March 31, 2022
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun HAN, Hassan JAVANBAKHT, Henrik MUELLER, Yongguang WANG, Song YANG
  • Patent number: 11191775
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: December 7, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun Han, Hassan Javanbakht, Henrik Mueller, Yongguang Wang, Song Yang
  • Patent number: 10953034
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: March 23, 2021
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • Publication number: 20200147123
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: October 23, 2019
    Publication date: May 14, 2020
    Applicant: HOFFMAN-LA ROCHE INC.
    Inventors: Susanne KAMMLER, Anaïs LOPEZ, Henrik MUELLER, Søren OTTOSEN, Lykke PEDERSEN
  • Publication number: 20190216846
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for inhibitors of PAPD5 or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.
    Type: Application
    Filed: June 19, 2017
    Publication date: July 18, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Hassan JAVANBAKHT, Søren OTTOSEN, Lykke PEDERSEN, Henrik MUELLER
  • Publication number: 20190194768
    Abstract: The present invention relates to a method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection, wherein a compound that (i) reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7); and/or (ii) binds to PAPD5 and/or PAPD7 and inhibits 5 propagation of HBV; is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. The invention also provides for an inhibitor of PAPD5 and/or PAPD7 for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection. Also comprised in the present invention is a 10 pharmaceutical composition for use in the treatment and/or prevention of a HBV infection, and a method for monitoring the therapeutic success during the treatment of a HBV infection.
    Type: Application
    Filed: June 19, 2017
    Publication date: June 27, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Xingchun HAN, Hassan JAVANBAKHT, Henrik MUELLER, Yongguang WANG, Song YANG
  • Publication number: 20190111073
    Abstract: The present invention relates to nucleic acid molecules that are complementary to both PAP associated domain containing 5 (PAPD5) and PAP associated domain containing 7 (PAPD7), leading to inhibition of the expression of both PAPD5 and PAPD7 when using a single nucleic acid molecule. The invention also provides for PAPD5 and PAPD7 specific nucleic acid molecules for use in treating and/or preventing a HBV infection, in particular a chronic HBV infection. Also comprised in the present invention is a pharmaceutical composition for use in the treatment and/or prevention of a HBV infection.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 18, 2019
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Susanne Kammler, Anaïs Lopez, Henrik Mueller, Søren Ottosen, Lykke Pedersen
  • Patent number: 9834930
    Abstract: Glazings comprising first and second channel-section glazing elements are described. The first and second channel-section glazing elements are arranged to define a cavity in which is located an inner glazing element comprising a glass glazing element, in particular a soda-lime-silica glass sheet, channel-section glazing element or sheet of rolled glass having at least one fire polished edge. The inner glazing element divides the cavity into at least two spaces to improve the thermal and/or noise performance of the glazing. By using low emissivity coatings on one or more major surfaces of one or more of the glazing elements, the thermal performance may be further improved. Mechanical performance may be modified by the particular type of inner glazing element used. It is possible to retrofit existing glazings to improve the thermal and/or noise performance thereof.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: December 5, 2017
    Assignees: Pilkington Deutschland AG, Bauglasindustrie GmbH
    Inventors: Thomas Braun, Christoph Claesges, Wolfgang Dutt, Kurt-Henrik Mueller
  • Publication number: 20160138266
    Abstract: Glazings comprising first and second channel-section glazing elements are described. The first and second channel-section glazing elements are arranged to define a cavity in which is located an inner glazing element comprising a glass glazing element, in particular a soda-lime-silica glass sheet, channel-section glazing element or sheet of rolled glass having at least one fire polished edge. The inner glazing element divides the cavity into at least two spaces to improve the thermal and/or noise performance of the glazing. By using low emissivity coatings on one or more major surfaces of one or more of the glazing elements, the thermal performance may be further improved. Mechanical performance may be modified by the particular type of inner glazing element used. It is possible to retrofit existing glazings to improve the thermal and/or noise performance thereof.
    Type: Application
    Filed: July 18, 2014
    Publication date: May 19, 2016
    Inventors: THOMAS BRAUN, CHRISTOPH CLAESGES, WOLFGANG DUTT, KURT-HENRIK MUELLER
  • Patent number: 6257243
    Abstract: The invention relates to a coaxial smoking article, particularly a coaxial cigarette, comprising a coaxial rod of smokable material, which rod has an inner segment (1) of smokable material surrounded by a covering (2), around which covering is an outer segment (3) of combustible or thermally destructible/decomposable material, which outer segment is also surrounded by a covering (4). The combustible or thermally destructible/decomposable material of the outer segment contains no or only a very small proportion of spot-forming substances. Further, the coverings of the inner and outer segments are such that spot-forming substances in the inner segment are essentially unable to reach the outside of the covering. Hence, a cigarette having reduced potential for the production of spotting is so formed.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: July 10, 2001
    Assignee: Brown & Williamson Tobacco Corporation
    Inventors: Bernd-Henrik Müller, Adolf Schlüter, Werner Schneider, Christopher John Cook, Joseph Wanna, Frank Kelley St. Charles
  • Patent number: 5859855
    Abstract: A private communication system and an allocated, private communication terminal equipment that is not directly connectable, i.e. that is "external", has a respective terminal equipment emulation unit allocated to it. This terminal equipment emulation unit pair are connectable to one another at least via a public dialed communication network, where the connection of at least one message path and of an additional signaling path is controlled via the public dialed communication network and the switching of the paths suited to the terminal equipment emulation unit pair is checked. With the assistance of the terminal equipment emulation unit pair, isolated or external communication terminal equipment can be connected without diminishing the scope of performance features of private communication networks. Misconnections and false signalings are avoided by checking the connection suited to the terminal equipment emulation unit pair with the assistance of a specific check procedure.
    Type: Grant
    Filed: July 22, 1996
    Date of Patent: January 12, 1999
    Assignee: Siemens Aktiengesellschaft
    Inventor: Henrik Mueller
  • Patent number: 5453984
    Abstract: Communication system for multi-service communication terminal equipment in local networks. A local network in which communication terminal equipment (KE; "multi media" communication terminal equipment) additionally having narrow-band and telephone services (SB, FE) are provided in addition to network-specific services is connected via an interworking unit (APE) to subscriber line interfaces (TAS) of a communication system (KA) having narrow band and telephone communication functions (SB, FE). As a result of the insertion of an interworking unit (APE) equipped with subscriber equipment (TLE), a matching unit (AE) and an access means (LANZ) onto the local network (LAN), the functions of both networks (narrow band and telephone network and local network LAN) are preserved largely unmodified and a maximally possible modularity and flexibility given the least additional outlay are achieved in structuring and formatting communication systems with "multi media" communication terminal equipment.
    Type: Grant
    Filed: June 18, 1993
    Date of Patent: September 26, 1995
    Assignee: Siemens Aktiengesellschaft
    Inventor: Henrik Mueller